Cumberland Pharmaceuticals is a specialty pharmaceutical company organized around acquiring, developing and commercializing branded prescription products designed to improve quality of care and address unmet medical needs. With emphasis on improving patient care and products that offer clear advantages over existing treatments while also delivering solutions to help reduce costs for healthcare providers, the firm has focused most of its attention on underserved niche markets, including hospital acute care and gastroenterology, to deliver products and serve patients in the U.S. market. Cumberland also makes its products available to patients internationally through select strategic partnerships. Cumberlands product portfolio includes Acetadote (acetylcysteine), an injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen), an injection for pain and fever; and Kristalose (lactulose), a prescription laxative administered orally for the treatment of constipation. The company has a collaboration agreement with Vanderbilt University to develop a palliative treatment for fluid buildup in the lungs of cancer patients, as well as a novel treatment to improve renal function in patients with hepatorenal syndrome. It also has collaboration agreements with the University of Mississippi to develop an injectable anti-infective to treat fungal infections in immuno-compromised patients and a collabroation with the University of Tennessee to develop a novel asthma therapeutic to prevent remodeling of airway smooth muscle to reduce asthmatic reaction in pediatric patients.
